August 03, 2018
The Patent Trial and Appeal Board has turned down Pfizer Inc.'s challenge to a patent covering Genentech Inc.'s blockbuster cancer treatment Avastin, finding the challenger couldn't prove the patent shouldn't have been issued.
January 03, 2018
Amgen Inc. in a brief unsealed Tuesday urged a Delaware federal judge to dismiss a claim by Genentech Inc. that it had breached a "binding" representation that it would market its biosimilar of cancer drug Avastin at a certain date, arguing the biotechnology rival "mischaracterize[d]" Amgen's statement.
October 27, 2017
Amgen Inc. has been "completely ignoring" its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly unsealed complaint.